Table 5.

Effects of each treatment on TXB₂, 6-keto-PGF_1α and the TXB₂/6-keto-PGF_1a ratio in k-carrageenan-induced rat tail thrombosis model (n = 10)

Groups	TXB2	6-keto-PGFlα	TXB2/6-keto-PGFlα
Control	498 ± 32##	889 ± 28##	0.56 ± 0.04##
Model	696 ± 39	586 ± 24	1.19 ± 0.08
CMC-Na	703 ± 37	550 ± 22##	1.28 ± 0.08##
Aspirin	658 ± 44*	741 ± 23**	0.89 ± 0.06**
Eugenol	678 ± 58	699 ± 30**	0.97 ± 0.09**
AEE L	605 ± 22**	667 ± 17**	0.91 ± 0.04**
AEE M	612 ± 45**	737 ± 13**	0.83 ± 0.07**
AEE H	644 ± 23**	599 ± 26**	1.08 ± 0.07**
Combination	598 ± 51**	701 ± 31**	0.86 ± 0.10**

Blood samples anticoagulated with EDTA-K₂ were centrifuged at 1000 g for 10 min to obtain plasma, which was analyzed using ELISA kits. Data are expressed as mean ± SD. ^## P < 0.01 compared with the model group. *P < 0.05, **P < 0.01 compared with the CMC-Na group. AEE L: AEE 18 mg/kg; AEE M: 36 mg/kg; AEE H: AEE 72 mg/kg; Combination: combination of aspirin and eugenol (molar ratio 1:1)